Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
I think it’s weird you’ve made the assumption these professionals buying this haven’t already considered the things you’ve said… like that’s all looked at during the acquisition process